Group Leader - AAV-Exosome based gene therapy at Evox Therapeutics
Dr. Rahul Kaushik has 13+ years of R&D experience with strong scientific background in viral and non-viral gene delivery technologies and innovations (rAAV, LVV and Exosomes) targeting various diseases and tissues (CNS, retina and liver). As a Group Leader at Evox Therapeutics, he develops innovative platform technologies to address challenges related to immunogenicity, toxicity, and repeated dosing associated with rAAV based in-vivo gene therapy. He leads the AAV and ExoAAV production team creating in-house capabilities for the development of gene therapy products and platforms.
With 7+ years of multidisciplinary team leadership, Dr. Kaushik designs scientific strategies and innovative gene therapy solutions. His expertise spans AAV biology, technological advancements, and rare diseases. Previously, he focused on rAAV-based ocular gene therapy for large genes and led rAAV and LV platform technologies for the gene manipulation and editing in CNS space as Head of AAV Facility and Molecular Biology at the German Center for Neurodegenerative Diseases (DZNE). He specializes in vector design, lead candidate selection, capsid selection, initial process and analytical development, tech transfer, managing CROs/CDMOs, designing POC, IND enabling preclinical rodent and NHP studies for dose finding, biodistribution, PK/PD, and toxicity to collect safety and efficacy data.
Dr. Kaushik’s 20+ publications in prestigious journals such as Science, Cell, Nature Communications, EMBO, and Progress in Neurobiology showcase his molecular expertise for genetic manipulations. He is deeply passionate about leveraging next-generation engineered viral vectors and enhancing manufacturing processes to develop gene therapy products that can combat devastating human diseases.